alpha-aminopyridine has been researched along with Adverse Drug Event in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 10 (62.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, JM; de Botton, S; DiNardo, CD; Döhner, H; Fathi, AT; Frattini, MG; Gong, J; Hasan, M; Kantarjian, HM; Lersch, F; Martin-Regueira, P; Montesinos, P; Schuh, AC; Stein, EM; Vyas, P; Wei, AH; Zeidan, AM | 1 |
| Ahle, G; Arrondeau, J; Cortot, A; De Crozals, F; Duflot-Boukobza, A; Fallet, V; Lena, H; Naltet, C; Rouby, P | 1 |
| Fan, Y; Hong, Z; Jia, F; Li, G; Li, J; Li, Y; Liu, Z; Lu, S; Lu, Y; Wu, YL; Zhou, J; Zhou, Q | 1 |
| Araz, M; Artaç, M; Er, MM; Eryılmaz, MK; Hendem, E | 1 |
| Gome, J; Hayes, T; Teo, SW | 1 |
| Barker, D; Burr, L; Dorahy, D; France, M; Greville, H; Middleton, P; Tong, K; Visser, S; Wainwright, C; Wark, P | 1 |
| Fukuhara, K; Goto, Y; Hayashi, H; Hida, T; Morise, M; Nagasawa, T; Niho, S; Nishio, M; Nogami, N; Ohkura, M; Peltz, G; Sakakibara-Konishi, J; Satouchi, M; Seto, T; Suzuki, M; Takahashi, T; Thurm, H | 1 |
| Bridges, A; Gleue, CA; Shah, K; Wentworth, A | 1 |
| Doerler, M; Gambichler, T; Ocker, L; Stranzenbach, R; Susok, L | 1 |
| Chen, J; Clancy, J; Hibma, J; James, LP; Peltz, G; Ruiz-Garcia, A; Thurm, H | 1 |
| Catherinot, E; Chabrol, A; Chaumais, MC; Couderc, LJ; Doubre, H; Fraboulet, S; Friard, S; Hamid, AM; Mayenga, M; Metivier, AC; Montani, D; Rivaud, E; Salvator, H; Tcherakian, C | 1 |
| Bauer, TM; Chioda, MD; Felip, E; Peltz, G; Shaw, AT; Solomon, BJ; Thurm, H | 1 |
| Arkenau, HT; Auger, KR; Blagden, SP; Fleming, RA; Gazzah, A; Greystoke, A; Mak, G; Mazumdar, J; Nebot, N; Plummer, R; Rizzuto, I; Rogan, D; Soria, JC; Tolson, J; Yan, L; Zhang, J | 1 |
| Janez, A; Jensterle, M; Kocjan, T | 1 |
| Arkenau, HT; Auger, KR; Bahleda, R; Blagden, SP; Brown, J; Dean, E; Evans, TR; Fleming, RA; Gan, HK; Gibson, D; Hollebecque, A; Lemech, C; Mazumdar, J; Millward, M; Murray, S; Nebot, N; Peddareddigari, V; Plummer, R; Ranson, M; Singh, R; Soria, JC; Swartz, L; Zalcman, G | 1 |
| Cai, Y; Chen, F; Chen, Q; Lin, M; Liu, J; Shi, J; Wang, Y; Wang, Z; Zeng, X; Zhang, Y; Zhou, H | 1 |
1 review(s) available for alpha-aminopyridine and Adverse Drug Event
| Article | Year |
|---|---|
[Central nervous system disorders on lorlatinib: How to detect and manage in practice?]
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Drug-Related Side Effects and Adverse Reactions; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quality of Life | 2022 |
6 trial(s) available for alpha-aminopyridine and Adverse Drug Event
| Article | Year |
|---|---|
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
Topics: Aged; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Progression-Free Survival; Random Allocation; Treatment Outcome; Triazines | 2021 |
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypercholesterolemia; Lactams; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Risk Assessment; Treatment Outcome | 2021 |
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
Topics: Aged; Aminopyridines; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hydroxamic Acids; Male; Mesothelioma; Middle Aged; Neoplasms; Progression-Free Survival; Pyridones; Pyrimidinones | 2019 |
Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.
Topics: Adult; Aminopyridines; Benzamides; Body Weight; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Insulin; Menstrual Cycle; Metformin; Molecular Targeted Therapy; Obesity; Phosphodiesterase 4 Inhibitors; Polycystic Ovary Syndrome; Sex Hormone-Binding Globulin; Testosterone | 2014 |
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Biopsy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neurofibromin 2; Protein Kinase Inhibitors | 2016 |
An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial.
Topics: Adhesives; Adolescent; Adult; Aged; Aminopyridines; Anti-Allergic Agents; Cohort Studies; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Erythema; Female; Humans; Male; Middle Aged; Pain; Pharmaceutical Vehicles; Stomatitis, Aphthous; Tablets | 2006 |
9 other study(ies) available for alpha-aminopyridine and Adverse Drug Event
| Article | Year |
|---|---|
[Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib].
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; China; Consensus; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles | 2022 |
Ribociclib-induced hepatotoxicity.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Protein Kinase Inhibitors; Purines | 2023 |
Ribociclib may potentiate rosuvastatin effect in causing late onset rhabdomyolysis.
Topics: Aminopyridines; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Purines; Rhabdomyolysis; Rosuvastatin Calcium | 2023 |
Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease.
Topics: Administration, Intravenous; Adult; Aminophenols; Aminopyridines; Anti-Bacterial Agents; Australia; Benzodioxoles; Case-Control Studies; Chloride Channel Agonists; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Forced Expiratory Volume; Humans; Male; Mutation; Quinolones; Respiratory Function Tests; Respiratory Tract Infections; Symptom Flare Up | 2020 |
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Topics: Aged; Aged, 80 and over; Aminopyridines; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Hypercholesterolemia; Lactams; Lactams, Macrocyclic; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrazoles | 2020 |
Cutaneous sarcoid-like drug reaction caused by an anaplastic lymphoma kinase inhibitor.
Topics: Adenocarcinoma of Lung; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Biopsy; Carbazoles; Cell Cycle Proteins; Drug-Related Side Effects and Adverse Reactions; Female; Granuloma; Humans; Lactams; Microtubule-Associated Proteins; Neoplasm Staging; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Sarcoidosis; Serine Endopeptidases; Skin; Withholding Treatment | 2021 |
Acute generalised exanthematous pustulosis after initiation of palbociclib therapy for metastatic breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; Piperazines; Purines; Pyridines | 2021 |
Lorlatinib - Induced pulmonary arterial hypertension.
Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Vascular Resistance; Walk Test; Withholding Treatment | 2018 |
Clinical Management of Adverse Events Associated with Lorlatinib.
Topics: Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Severity of Illness Index; Treatment Outcome | 2019 |